Sarah Ferber - Orgenesis Insider

ORGS -- USA Stock  

USD 5.60  0.02  0.36%

  Executive
Prof. Sarah Ferber, Ph.D., is Chief Scientific Officer of Orgenesis Inc. Prof. Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aharon Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a postdoctoral fellowship at the Joslin Diabetes Lab at Harvard Medical School. Prof. Ferbers breakthrough discovery suggested that humans carry their own stemcells throughout adulthood, thus obviating the need for embryonic stem cells for generating an organ in need. Most of the research was conducted in Prof. Ferbers lab, in the Endocrine Research Lab at the Sheba Medical Center, and currently employs 11 scientists. Prof. Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferbers research work was funded over the past 10 years by the JDRF, the Israel Academy of Science foundation and DCure.
Age: 59  Executive Since 2012      
480-659-6404  http://www.orgenesis.com
Sarah Ferber received TEVA, LINDNER, RUBIN and WOLFSON awards for this research. Prof. Ferber research work was funded over the past 10 years by the JDRF, the Israel Academy of Science foundation and DCure.

Management Efficiency

The company has return on total asset (ROA) of (15.85) % which means that it has lost $15.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (55.97) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.83 M in liabilities with Debt to Equity (D/E) ratio of 8.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Orgenesis has Current Ratio of 1.04 suggesting that it may not be capable to disburse its financial obligations when they are due.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Lee AllenDova Pharmaceuticals
2017
Wolfgang ArnoldAuris Medical Holding AG
2007
Sonja NelsonNantKwest
2018
Pankaj BhargavaDicerna Pharmaceuticals
2014
Herbert DOEdge Therapeutics
N/A
Carole HoDenali Therapeutics
N/A
Oliver KubliAuris Medical Holding AG
2010
Anne ZollerAuris Medical Holding AG
2015
Andrea BraunAuris Medical Holding AG
2016
Albert IIEdge Therapeutics
N/A
Thomas JungAuris Medical Holding AG
2016
Bettina StubinskiAuris Medical Holding AG
2013
Herbert FaleckEdge Therapeutics
2013
Albert MarchioEdge Therapeutics
2017
Beth TaylorEndocyte
2016
Cindy McGeeAuris Medical Holding AG
2016
James WeissmanDicerna Pharmaceuticals
2012
Gregory GinEdge Therapeutics
2018
Alison ArmourEndocyte
2015
Ralf RosskampDicerna Pharmaceuticals
2017

Entity Summary

Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 103 people.Orgenesis (ORGS) is traded on BATS Exchange in USA. It is located in MARYLAND U.S.A and employs 103 people. Orgenesis is listed under Pharmaceutical Products category by Fama And French industry classification.

Orgenesis Leadership Team

David Sidransky, Director
Yaron Adler, Director
Marie Bouillez, Director
Neil Reithinger, CFO, Treasurer and Secretary
Scott Carmer, CEO of Orgenesis Maryland Inc
Etti Hanochi, Director
Hugues Bultot, Director
Guy Yachin, Director
Chris Buyse, Director
Vered Caplan, Chairman of the Board, Interim President and CEO
Sarah Ferber, Chief Scientific Officer

Stock Performance Indicators

Current Sentiment - ORGS

Orgenesis Investor Sentiment

Most of Macroaxis users are now bullish on Orgenesis. What is your perspective on investing in Orgenesis? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally take a look at Your Equity Center. Please also try Portfolio Reporting module to create custom reports across your portfolios and generate quick suggestion pitch.
Search macroaxis.com